Health Canada has amended the Prescription Drug List (PDL) to require a prescription for all sleep-related use of melatonin in children and adolescents under 18 years of age. The amendment, published June 2, 2026, broadens an earlier qualifier that had been in place since September 2025 and was limited to melatonin used for insomnia in children with Autism Spectrum Disorder or Smith-Magenis syndrome. Under the updated listing, pediatric melatonin prescription drug requirements in Canada now apply to any sleep-related indication in those under 18, regardless of condition.
The change affects how melatonin products are classified under the Food and Drugs Act. Any drug containing melatonin sold for sleep-related use in the pediatric population is now a prescription drug under the Food and Drug Regulations. Existing licensed NHPs containing melatonin are not affected by this amendment, as all currently authorized melatonin NHPs are indicated for adult use only.
How the PDL Qualifier Changed
The September 2025 qualifier was narrow by design. It captured melatonin only when sold for the treatment of insomnia in children aged 2 to under 18 with ASD or Smith-Magenis syndrome. The June 2026 amendment replaces that qualifier with broader language: melatonin or its salts, when sold for sleep-related use in children and adolescents under 18 years of age.
The effect is a significant expansion in scope. Where the 2025 qualifier applied to a specific diagnosis-based use case, the 2026 amendment covers the full range of sleep-related indications in the pediatric population. Health Canada concluded that physician supervision is necessary for this age group in order to rule out underlying health conditions contributing to sleep problems, to guide caregivers on sleep hygiene practices that should be tried first, and to determine appropriate dosing based on individual health needs.
The NHP Pathway for Pediatric Melatonin Was Already Closed
An important point for NHP licence holders to understand: this amendment formalizes a restriction that the NHP framework had already effectively put in place. The current NNHPD melatonin monographs, both oral and sublingual and updated in 2024, are limited to adult indications. There are no authorized NHPs containing melatonin with pediatric indications in Canada, and there was no NHP pathway available for companies seeking to add pediatric claims to melatonin products prior to this amendment.
The one authorized product for pediatric melatonin use in Canada is Slenyto, a prolonged-release prescription drug authorized for treating insomnia in children aged 2 to under 18 with ASD or Smith-Magenis syndrome. Slenyto will continue to fall within the amended PDL qualifier. Companies wishing to market melatonin for sleep-related use in the pediatric population must now pursue a Drug Identification Number (DIN) through Health Canada’s Pharmaceutical Drugs Directorate under the Food and Drug Regulations.
Transition Timeline and Compliance Expectations
Health Canada has indicated a transition period to allow affected licence holders to adjust their product registrations, labelling, and distribution arrangements. The exact duration of this transition period will be confirmed in the final notice, but companies should not wait for the final publication date to begin preparing. Regulatory transitions of this nature typically involve a defined wind-down period during which existing NHP-licensed stock may continue to be sold, followed by a hard compliance deadline after which only prescription-authorized products may remain on the market.
Affected companies will need to determine whether to reformulate their products to remove pediatric claims and maintain NHP status, or to pursue a Drug Identification Number (DIN) through the prescription drug authorization pathway. Each path carries different timelines, cost profiles, and regulatory requirements, and the right strategy will depend on the company’s product portfolio and market positioning.
What This Means for Your Business
1. If Your Melatonin Product Is Adult-Only
For most NHP licence holders, this amendment has no immediate operational impact, provided their melatonin products are accurately labelled and positioned for adult use only. The critical question is whether any current product label, dosing table, or marketing material contains language that could be read as directing melatonin use toward children.
This includes e-commerce listings, social media content, and retailer product descriptions. Even implicit pediatric positioning, such as child-friendly product formats or imagery, could draw regulatory scrutiny under the new framework. A straightforward audit of all consumer-facing materials is the practical first step to confirm that adult-only positioning is unambiguous and consistent across all channels.
2. If You Were Exploring a Pediatric Melatonin Product
Companies that have been assessing whether a pediatric melatonin NHP could be viable now have a definitive answer: that pathway is closed. Any product seeking to make sleep-related claims for children or adolescents under 18 must be authorized as a prescription drug.
3. Pursuing the Prescription Drug Pathway
That is a substantially different regulatory undertaking from NHP licensing. It involves pharmaceutical-grade evidence standards, a New Drug Submission or Abbreviated New Drug Submission through the Pharmaceutical Drugs Directorate, and post-market surveillance obligations. Guidance on Canada’s NHP licensing requirements and OTC drug compliance pathways can help companies determine which regulatory route applies to their specific situation.
Frequently Asked Questions
Does this amendment affect adult melatonin NHPs currently on the market?
No. The PDL qualifier is specifically scoped to sleep-related use in children and adolescents under 18. Melatonin NHPs authorized for adult use only are not affected by the June 2026 amendment and continue to be regulated under the Natural Health Products Regulations as before. Licence holders should confirm that their product labelling, dosing instructions, and marketing materials contain no pediatric claims or indications.
Can a company remove pediatric claims from its melatonin product to maintain NHP status?
In principle, a product with no pediatric indications, dosing, or marketing falls outside the scope of the PDL qualifier. However, removing claims is not as simple as updating a label. Companies must submit a formal amendment to their NHP licence through the NNHPD and ensure all consumer-facing materials, including retailer listings and digital content, are updated consistently. Health Canada may also assess whether a product’s format or branding implicitly targets children, independent of label wording.
What must a company do if it wants to market melatonin for pediatric sleep use in Canada?
Any company wishing to market melatonin for sleep-related use in children or adolescents under 18 must seek authorization under the Food and Drug Regulations through Health Canada’s Pharmaceutical Drugs Directorate. This involves a drug submission process with pharmaceutical-grade evidence requirements, which is a materially different pathway from the NHP licensing process. The Pharmaceutical Drugs Directorate can be reached at bcansenquiries@hc-sc.gc.ca.
Key Takeaways
- Health Canada’s June 2, 2026 PDL amendment makes melatonin a prescription drug for all sleep-related use in children and adolescents under 18, not only for specific diagnoses as the 2025 qualifier required.
- The amendment is in effect as of June 2, 2026. There is no transition period referenced in the Health Canada notice.
- Existing adult-use melatonin NHPs are not affected, provided their labelling and marketing contain no pediatric indications.
- The NHP pathway for pediatric melatonin claims was already effectively closed under the current NNHPD monographs; this amendment makes that restriction explicit in the PDL.
- Companies wishing to market melatonin for pediatric sleep use must pursue a DIN through Health Canada’s Pharmaceutical Drugs Directorate under the Food and Drug Regulations.
- All melatonin product labels, NHP licence conditions, and consumer-facing materials should be audited to confirm adult-only positioning is clear and consistent.
Preparing for the Change Ahead
For companies with melatonin products in their Canadian portfolio, the priority right now is clarity on positioning. A thorough review of all product labels, NHP licence conditions, and consumer-facing materials will confirm whether current products fall within or outside the scope of the amended PDL qualifier.
Companies repositioning existing melatonin products to remove any pediatric claims will need to submit a licence amendment through the NNHPD and update all downstream marketing consistently. For those considering the prescription drug route, early planning is essential given the evidence requirements and submission timelines involved. Quality Smart Solutions works with NHP licence holders and companies navigating Canada’s OTC and prescription drug compliance pathways to develop a clear path forward.
To discuss how this amendment affects your specific product portfolio, learn more about NHP licensing and compliance support or contact Quality Smart Solutions directly.
